Credit Suisse Group set a $86.00 target price on Clovis Oncology (NASDAQ:CLVS) in a report issued on Thursday morning. The firm currently has a buy rating on the biopharmaceutical company’s stock. The analysts noted that the move was a valuation call.

CLVS has been the subject of a number of other research reports. Zacks Investment Research upgraded shares of Clovis Oncology from a hold rating to a buy rating and set a $95.00 target price for the company in a research note on Tuesday, October 17th. Oppenheimer restated a hold rating on shares of Clovis Oncology in a research note on Tuesday, October 10th. BidaskClub upgraded shares of Clovis Oncology from a strong sell rating to a sell rating in a research note on Saturday, December 9th. JPMorgan Chase & Co. restated a buy rating on shares of Clovis Oncology in a research note on Thursday, January 11th. Finally, Leerink Swann restated an outperform rating and set a $90.00 target price (down previously from $107.00) on shares of Clovis Oncology in a research note on Wednesday, November 15th. Two investment analysts have rated the stock with a sell rating, seven have issued a hold rating and twelve have issued a buy rating to the company’s stock. The company has an average rating of Hold and an average target price of $90.43.

Shares of Clovis Oncology (NASDAQ:CLVS) traded up $0.89 during mid-day trading on Thursday, reaching $56.76. 842,600 shares of the company’s stock were exchanged, compared to its average volume of 1,397,531. The firm has a market capitalization of $2,940.00, a PE ratio of -6.86 and a beta of 1.38. The company has a current ratio of 3.19, a quick ratio of 3.16 and a debt-to-equity ratio of 0.94. Clovis Oncology has a 12-month low of $45.42 and a 12-month high of $99.45.

Clovis Oncology (NASDAQ:CLVS) last posted its earnings results on Wednesday, November 1st. The biopharmaceutical company reported ($1.24) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($1.18) by ($0.06). The company had revenue of $16.81 million for the quarter, compared to analyst estimates of $21.12 million. Clovis Oncology had a negative return on equity of 122.06% and a negative net margin of 947.47%. During the same quarter in the prior year, the business posted ($1.70) EPS. research analysts expect that Clovis Oncology will post -7.65 EPS for the current fiscal year.

In other Clovis Oncology news, Director Thorlef Spickschen sold 4,500 shares of the firm’s stock in a transaction dated Monday, January 8th. The shares were sold at an average price of $64.97, for a total value of $292,365.00. Following the transaction, the director now directly owns 21,118 shares of the company’s stock, valued at approximately $1,372,036.46. The transaction was disclosed in a legal filing with the SEC, which is available through this link. Also, insider Gillian C. Ivers-Read sold 3,000 shares of the firm’s stock in a transaction dated Wednesday, November 15th. The shares were sold at an average price of $63.70, for a total transaction of $191,100.00. The disclosure for this sale can be found here. Insiders sold a total of 18,000 shares of company stock valued at $1,123,425 in the last quarter. Corporate insiders own 12.50% of the company’s stock.

A number of hedge funds have recently added to or reduced their stakes in CLVS. Schwab Charles Investment Management Inc. increased its holdings in Clovis Oncology by 8.6% in the 2nd quarter. Schwab Charles Investment Management Inc. now owns 189,627 shares of the biopharmaceutical company’s stock valued at $17,755,000 after buying an additional 14,961 shares during the period. Legal & General Group Plc increased its holdings in Clovis Oncology by 24.5% in the 2nd quarter. Legal & General Group Plc now owns 15,693 shares of the biopharmaceutical company’s stock valued at $1,462,000 after buying an additional 3,090 shares during the period. Prudential Financial Inc. increased its holdings in Clovis Oncology by 15.5% in the 2nd quarter. Prudential Financial Inc. now owns 4,388 shares of the biopharmaceutical company’s stock valued at $411,000 after buying an additional 590 shares during the period. Principal Financial Group Inc. increased its holdings in Clovis Oncology by 595.2% in the 2nd quarter. Principal Financial Group Inc. now owns 47,385 shares of the biopharmaceutical company’s stock valued at $4,436,000 after buying an additional 40,569 shares during the period. Finally, Aberdeen Asset Management PLC UK bought a new position in Clovis Oncology in the 2nd quarter valued at about $549,000.

ILLEGAL ACTIVITY NOTICE: This report was posted by Watch List News and is the property of of Watch List News. If you are reading this report on another publication, it was copied illegally and republished in violation of US and international trademark and copyright law. The original version of this report can be viewed at https://www.watchlistnews.com/credit-suisse-group-reiterates-86-00-price-target-for-clovis-oncology-clvs/1818292.html.

Clovis Oncology Company Profile

Clovis Oncology, Inc is a biopharmaceutical company focused on acquiring, developing and commercializing anti-cancer agents in the United States, Europe and other international markets. The Company’s product candidates include Rociletinib, Rubraca (Rucaparib) and Lucitanib. Rucaparib is an oral, small molecule poly adenosine diphosphate (ADP)-ribose polymerase (PARP) inhibitor of PARP1, PARP2 and PARP3 approved as a monotherapy for the treatment of patients with deleterious breast cancer (BRCA) (human genes associated with the repair of damaged deoxyribonucleic acid (DNA)) mutation (germline and/or somatic) associated advanced ovarian cancer.

Analyst Recommendations for Clovis Oncology (NASDAQ:CLVS)

Receive News & Ratings for Clovis Oncology Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Clovis Oncology and related companies with MarketBeat.com's FREE daily email newsletter.